Pooled together, the 418 patients had an ORR of 32%; the ORR in PTCL-NOS patients was 29%, in ALK-negative ALCL was 27% (95% CI, 16–38%), while in the AITL subgroup was 44%, strongly indicating a more efficient response compared to other subgroups (p = 0.01). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.